ORCHIDPHAR

Orchid Pharma Limited has informed the Exchange regarding 'FORM G -INVITATION FOR RESOLUTION PLANS -INSOLVENCY AND BANKRUPTCY BOARD OF INDIA (INSOLVENCY RESOLUTION PROCESS FOR CORPORATE PERSONS) , REGULATIONS,2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Resolution plans-Insolvency and Bankruptcy Board of India ( Insolvency Resolution Process for Corporate Persons) Regulations, 2016.'.

Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

Orchid Pharma Limited has informed the Exchange regarding Board meeting held on March 16, 2018.

Orchid Pharma Limited has informed the Exchange regarding 'Extension of Date - Form G - Invitation for Resolution Plans-Insolvency and Bankruptcy Board of india ( Insolvancy Resolution Process for Corporate Persons) Regulations, 2016'.

Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Orchid Pharma Limited has informed the Exchange regarding Board meeting held on March 05, 2018.

Orchid Pharma Limited has informed the Exchange regarding 'Evaluation matrix for Resolution Applicants - Under Insolvency and Bankruptcy Board of India ( Insolvency Resolution process for Corporate persons ) Regulations'.

Orchid Pharma Limited has informed the Exchange regarding 'FORM G -INVITATION FOR RESOLUTION PLANS UNDER CORPORATE INSOLVENCY RESOLUTION PROCESS'.

Orchid Pharma Limited has informed the Exchange that INTIMATION REGARDING THE DATE OF RECEIPT OF TRADING APPROVAL UPON ALLOTMENT OF 37,02,450 EQUITY SHARES ON PREFERENTIAL BASIS

Orchid Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.

Orchid Pharma Limited has informed the Exchange regarding "Receipt Of Establishment Inspection Report (EIR) From USFDA - Post Marketing Adverse Drug Experience Reporting Inspection (PADE)".

Orchid Pharma Limited has informed the Exchange regarding Resignation of Mr R Kannan as Non- Executive Independent Director of the company w.e.f. December 27, 2017.

Orchid Pharma Limited has informed the Exchange regarding Resignation of Mr K N Venkatasubramanian as Non- Executive Independent Director of the company w.e.f. October 13, 2017.

The Exchange has sought clarification from Orchid Pharma Limited with respect to recent news item captioned "Aurobindo, DRL lead race to buy orchid". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Orchid Pharma Limited has submitted their response.

The Exchange has sought clarification from Orchid Pharma Limited with respect to recent news item captioned "Aurobindo, DRL lead race to buy orchid". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Orchid Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.

Orchid Pharma Limited has informed the Exchange regarding 'ANDA Approval From US FDA For Aripiprazole Orally Disintegrating Tablets'.

Orchid Pharma Limited has informed the Exchange regarding Updates- Quarterly Financial Results For Period Ended June 30 ,2017 And September 30, 2017.

Orchid Pharma Limited has informed the Exchange regarding 'Publication For Submission Of Expression Of Interest Under Insolvency And Bankruptcy Code,2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Appointment Of Resolution Professional (Rp) Under Insolvency And Bankruptcy Code,2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Postponement of Committee of Creditors Meeting'.

Orchid Pharma Limited has informed the Exchange regarding 'Committee of Creditors Meeting.'.

Orchid Pharma Limited has informed the Exchange that 'Orchid has received the Establishment Inspection Report ( EIR) from US FDA based on the successful inspection of the Active Pharmaceutical Ingredients ( API) manufacturing facility located at SIDCO Industrial Estate, Alathur Kanchipuram District, Tamil Nadu, India. This facility was inspected by US FDA in May 2017.'.

Orchid Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 13, 2017

Orchid Pharma Limited has informed the Exchange regarding voting results of Annual General Meeting held on September 13, 2017

Orchid Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 13, 2017

Orchid Pharma Limited has informed the Exchange regarding Annual General Meeting - Communication from the Interim Resolution Professional (IRP)

Orchid Pharma Limited has informed the Exchange regarding 'Regulation 30 of the SEBI( Listing Obligations and Disclosure Requirements) Regulations, 2015.

Orchid Pharma Limited has informed the Exchange regarding 'Intimation of Initiation of CIRP to regulatory Authorities.'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulations, 2015'.

Orchid Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 13, 2017

Orchid Pharma Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 7, 2017 to September 13, 2017(both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on September 13, 2017.

Orchid Pharma Limited has informed the Exchange regarding SETTLEMENT ORDER FROM SECURITIES AND EXCHANGE BOARD OF INDIA(SEBI) IN RESPECT OF ORCHID PHARMA LIMITED

Orchid Pharma Limited has informed the Exchange regarding Notice to shareholders Transfer of Equity Shares of the Company to Investor Education & Protection Fund ( IEPF) Suspense Account.

Orchid Pharma Limited has informed the Exchange regarding SUBMISSION OF AUDITED FINANCIALS IN THE REVISED FORMAT AS PER SCHEDULE III OF THE COMPANIES ACT,2013

Orchid Pharma Limited has informed the Exchange regarding Change in Statutory Auditor.

Orchid Pharma Limited has informed the Exchange regarding a press release dated May 26, 2017, titled "Press release issued in connection with Audited Financial Results of the Company for the year ended March 31, 2017".

Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 26, 2017.

Orchid Pharma Limited has informed the Exchange that Orchid has received ANDA approval from US FDA for Aripiprazole Tablets USP, 2 mg , 5Mg, 10mg, 20mg, and 30mg on May 24, 2017.

Orchid Pharma Limited has informed the Exchange regarding a press release dated April 18, 2017, titled "Establishment Inspection Report from USFDA".

Orchid Pharma Limited has informed the Exchange regarding Credit Rating

Rajagopal K has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

SBICAP Trustee Company Ltd. has submitted to the Exchange the disclosure under regulation 30(1) and 30(2) of SEBI (SAST) Regulations, 2011.

Promoters of the Company has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Pharma Limited has informed the Exchange regarding Intimation of Change in Name of Registry activity of our Registrar and Share Transfer Agent.

Orchid Pharma Limited has informed the Exchange regarding a press release dated February 07, 2017, titled "Press release issued in connection with Unaudited Financial Results of the Company for the Quarter ended December 31, 2016".

Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Orchid Pharma Limited has informed the Exchange regarding a press release dated November 09, 2016